Form 8-K - Current report:
SEC Accession No. 0001213900-24-005780
Filing Date
2024-01-23
Accepted
2024-01-23 16:45:15
Documents
14
Period of Report
2024-01-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea192032-8k_oramed.htm   iXBRL 8-K 45496
2 JOINT VENTURE AGREEMENT, DATED JANUARY 22, 2024, AMONG ORAMED PHARMACEUTICALS IN ea192032ex10-1_oramed.htm EX-10.1 438486
3 GRAPHIC ex10-1_001.jpg GRAPHIC 70082
  Complete submission text file 0001213900-24-005780.txt   834434

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ormp-20240122.xsd EX-101.SCH 3009
5 XBRL LABEL FILE ormp-20240122_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ormp-20240122_pre.xml EX-101.PRE 22355
8 EXTRACTED XBRL INSTANCE DOCUMENT ea192032-8k_oramed_htm.xml XML 3320
Mailing Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 646-844-1164
ORAMED PHARMACEUTICALS INC. (Filer) CIK: 0001176309 (see all company filings)

EIN.: 980376008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35813 | Film No.: 24553172
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)